Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 106 clinical trials
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent

glioblastoma multiforme
tumor progression
  • 14 views
  • 15 Dec, 2021
  • 4 locations
Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma

This is a phase I study to observe the safety and efficacy of irinotecan and bevacizumab combined with re-radiotherapy in the treatment of recurrent glioblastoma. The study will provide a higher

  • 0 views
  • 25 Mar, 2022
  • 1 location
Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma

A study to determine the feasibility and safety of individualized cancer stem cell targeted therapy based on high-throughput functional profiling of FDA/EMA-approved drugs in patients with GBM that has recurred or progressed following standards-of-care (RT, TMZ).

  • 0 views
  • 20 Sep, 2021
  • 1 location
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma

dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.

  • 0 views
  • 24 May, 2022
  • 1 location
Personalized Functional Profiling in Metastatic Gastrointestinal Cancer or Recurrent Glioblastoma Patients in Luxembourg.

The investigators are developing a novel standardized and centralized approach named Integrated Personalized Functional Profiling (PFP) in Luxembourg. Based on recent improvements in cancer biopsy-derived 3D-culture technologies the PFP process will screen patient derived cells (PDCs) with FDA/EMA-approved drugs to generate personalized functional response profiles. The selected drug through PFP …

glioblastoma multiforme
cancer treatment
  • 4 views
  • 16 Mar, 2022
  • 2 locations
TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.

neutrophil count
measurable disease
bevacizumab
glioblastoma multiforme
karnofsky performance status
  • 4 views
  • 17 Feb, 2022
  • 3 locations
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

This phase I trial studies the side effects and how well of pembrolizumab and a vaccine therapy (ATL-DC vaccine) work in treating patients with glioblastoma that has come back (recurrent) and can be removed by surgery (surgically accessible). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune …

surgical diagnosis
neutrophil count
glioblastoma multiforme
international normalized ratio
malignant glioma
  • 9 views
  • 19 Apr, 2022
  • 1 location
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

The aim of this study is to make preliminary assessment of PD-L1 and other immune related biomarkers that might act as predictors of anti-tumor activity of Nivolumab in patients with recurrent

recurrent disease
measurable disease
temozolomide
recurrent glioblastoma
glioblastoma multiforme
  • 0 views
  • 25 Jan, 2021
  • 1 location
Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)

The study will investigate combined stereotactic radiosurgery and enhanced immunotherapy for recurrent glioblastomas. Immune adjuvants will be injected intratumorally and systemically to induce

  • 0 views
  • 29 Nov, 2021
  • 1 location
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

The purpose of this study is to evaluate the efficacy and safety of GX-I7 in combination with bevacizumab in subjects with recurrent glioblastoma.

  • 0 views
  • 25 Mar, 2022
  • 1 location